Levente Meszaros
Corporate Officer/Principal chez RADIOPHARM THERANOSTICS LIMITED
Postes actifs de Levente Meszaros
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| RADIOPHARM THERANOSTICS LIMITED | Corporate Officer/Principal | 01/01/2022 | - |
NanoMab Technology Ltd.
 NanoMab Technology Ltd. Pharmaceuticals: MajorHealth Technology NanoMab Technology Ltd. is a Chinese biopharmaceutical company that focuses on developing radiopharmaceuticals for cancer precision therapies. NanoMab Technology is based in Shanghai, CN and was founded in 2016 by Hong-Hoi Ting and Henry Ho. The private company aims to address the unmet medical needs of cancer patients worldwide by developing a pipeline of theranostics using its proprietary camelid antibody platform. NanoMab has filed an IMPD on NM-01 with the UK Medical Healthcare Products Regulatory Agency and is developing its radio-labelled NM-02 for clinical trials in both imaging and treatment of breast and gastric cancers. The company's third program, NM-03, is a single domain antibody targeting a pan-cancer marker and is in preclinical development as a theranostic. | Directeur Technique/Scientifique/R&D | - | - |
Historique de carrière de Levente Meszaros
Statistiques
Internationale
| Chine | 2 |
| Australie | 2 |
Opérationnelle
| Corporate Officer/Principal | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectorielle
| Health Technology | 2 |
| Health Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| RADIOPHARM THERANOSTICS LIMITED | Health Services |
| Entreprise privées | 1 |
|---|---|
NanoMab Technology Ltd.
NanoMab Technology Ltd. Pharmaceuticals: MajorHealth Technology NanoMab Technology Ltd. is a Chinese biopharmaceutical company that focuses on developing radiopharmaceuticals for cancer precision therapies. NanoMab Technology is based in Shanghai, CN and was founded in 2016 by Hong-Hoi Ting and Henry Ho. The private company aims to address the unmet medical needs of cancer patients worldwide by developing a pipeline of theranostics using its proprietary camelid antibody platform. NanoMab has filed an IMPD on NM-01 with the UK Medical Healthcare Products Regulatory Agency and is developing its radio-labelled NM-02 for clinical trials in both imaging and treatment of breast and gastric cancers. The company's third program, NM-03, is a single domain antibody targeting a pan-cancer marker and is in preclinical development as a theranostic. | Health Technology |
- Bourse
- Insiders
- Levente Meszaros
- Expérience
